There are many benefits to exercise and how it can reduce the impact of the aging process. We have previously talked about how even a moderate amount of gentle exercise, such as walking, dancing, and strength training, can improve health and reduce mortality.
New research suggests that even moderate levels of physical activity can reduce glaucoma, one of the leading causes of blindness in the United States, and which is most prevalent among the elderly.
The data presented by UCLA researchers at the 121st Annual Meeting of the American Academy of Ophthalmology showed that the most physically active people involved in a recent study have a 73 percent reduced risk of developing glaucoma compared to the least active.
Every so often when talking about aging and eradicating age-related diseases someone will say there are other more important things that must be solved before we earn the right to live healthy and longer lives.
When you discuss any major issue, sooner or later someone will say it: there are more urgent issues than whatever it is you’re advocating for. Sometimes it may be true; other times, and probably most of the time, it’s a logical fallacy known as appeal to worse problems (or “not as bad as”, or even “fallacy of relative privation”).
For example, say you’ve got two issues, A and B, that cannot possibly be both dealt with at the same time; if A is life-threatening and B isn’t, well, then I think it’d make sense to reply “there are more urgent issues” to whoever suggests B should be taken care of first. However, all too often, this answer is abused to play down the importance of a problem that doesn’t happen to be one’s personal favourite—and yes, I’ve seen this happen with rejuvenation therapies.
To mark the letter’s 25th anniversary, researchers have issued a bracing follow-up. In a communique published Monday in the journal BioScience, more than 15,000 scientists from 184 countries assess the world’s latest responses to various environmental threats. Once again, they find us sorely wanting.
In 1992, scientists warned humanity about a host of impending ecological disasters. A quarter-century later, most of them have gotten worse.
The simple answer is, I don’t know. Probably we’ll see the first dog trials in the next year or two. If that works, human trials are another two years away, and eight years before they’re done. Once you get a few going and succeeding it’s a positive feedback loop.
George Church Will Make Virus-Resistant Organisms, Transplant Pig Organs to Humans, and Reverse Aging An interview with one of the most prolific scientists on earth in his lab at Harvard Medical School Photography by Maciek Jasik.
[p]Patients with junctional epidermolysis bullosa (JEB) carry mutations in genes that encode components of the basement membrane, which ensures the integrity between the epidermis and the dermis, such as laminin-332. These mutations cause blistering of the skin and chronic wounds. Following initial treatment of an adult patient with a limited affected region, Michele De Luca and colleagues reconstruct the full epidermis of a 7-year-old patient with autologous transgenic cells transduced with a virus vector carrying the non-mutated form of laminin-322.
In a move that can only be considered controversial, the first pig-human hybrid has been successfully created in a lab. Researchers managed to grow human cells inside early-stage pig embryos, which led to the creation of the first pig-human hybrids ever made. The result is described as interspecies chimeras.
Though the experiment is still in its early days, scientists think the “breakthrough” would possibly one day lead to lab-grown human organs that would be transplanted into people who need them. If the experiment is successful, hundreds of thousands of lives could be saved.
For the first time ever, scientists have attempted to cure a person’s disease by editing a gene inside the body.
Scientists used an IV to inject a patient with billions of copies of a corrective gene and a genetic tool to cut his DNA in a specific spot. “We cut your DNA, open it up, insert a gene, stitch it back up.”
Scientists have edited people’s genes in the past, but that work involved altering cells inside a lab and then returning them to the body, whereas the latest experiment was performed inside a person’s body.
He is the first patient to receive an experimental gene therapy as part of a clinical trial. Earlier this week, Sangamo Therapeutics injected Madeux with viruses containing a package of gene-editing material, according to the AP. The hope is that these viruses will enter Madeux’s cells, specifically liver cells, inject the missing gene at the right place in his DNA. Only about 1% of the liver’s cells need to be fixed, and give his liver the ability to produce the enzyme he has been missing all his life.
Brian Madeux’s life hasn’t been easy. So far, he’s had 26 operations to fix problems in everything from hernias to eyes. He has a rare disease called Hunter syndrome, which is caused by the lack of a gene that’s used to produce an enzyme that breaks down certain carbohydrates. As a result, the carbohydrates build up in his body’s cells causing all sorts of problems.
There is no cure. One way to deal with some of the symptoms is to receive regular doses of the missing enzyme, which may cost him in the US between $100,000 and $400,000 per year. Even then, the enzyme won’t reverse the damage made already and it won’t stop further deterioration that happens in the brain.
But Madeux’s life might be about to change. He is the first patient to receive an experimental gene therapy as part of a clinical trial. Earlier this week, Sangamo Therapeutics injected Madeux with viruses containing a package of gene-editing material, according to the AP. The hope is that these viruses will enter Madeux’s cells, specifically liver cells, inject the missing gene at the right place in his DNA. Only about 1% of the liver’s cells need to be fixed, and give his liver the ability to produce the enzyme he has been missing all his life.
